Abstracts Archive - Page 2412 of 2425 - ACR Meeting Abstracts

Abstract Number: 131 • 2012 ACR/ARHP Annual Meeting
Subclinical Arthritis Visualised by Positron Emission Tomography and Macrophage Targeting Precedes Clinical Flare in Rheumatoid Arthritis Patients in DAS28 Remission
Y.Y.J. Gent¹, A.E. Voskuyl¹, N. Ahmadi², N. Hoetjes³ and C.J. van der Laken¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Radiology, VU University Medical Center, Amsterdam, Netherlands, ³Nuclear Medicine & PET research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Macrophages play an important role in the pathophysiology of Rheumatoid Arthritis (RA). Targeting of macrophages by (R)-[11C]PK11195 positron emission tomography (PET) has previously been successfully…
Abstract Number: 132 • 2012 ACR/ARHP Annual Meeting
FDG-PET Evaluation of Axillary Lymph Nodes and Large Joints of Patients with Rheumatoid Arthritis Treated with Anti-TNF Drugs
Koichi Okamura¹, Yukio Yonemoto², Tetsuya Kaneko³, Kimihiko Takeuchi⁴, Tsutomu Kobayashi¹ and Kenji Takagishi¹, ¹Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ³Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan, ⁴Department of Rheumatology, Isesaki Fukushima Hospital, Isesaki, Gunma, Japan
Background/Purpose: F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to image synovial inflammation in patients with rheumatoid arthritis (RA). The development of molecular…
Abstract Number: 133 • 2012 ACR/ARHP Annual Meeting
Utility of PET-CT Imaging in IgG4-Related Disease
Arezou Khosroshahi¹, Leslie Lee², Mollie Carruthers¹, Rusen Acu², Pietro Bonaffini², Vikram Deshpande³, Dushyant Sahani² and John H. Stone¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Radiology, Massachusetts General Hospital, Boston, MA, ³Pathology, Massachusetts General Hospital, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition characterized by unique pathological features that affect a wide variety of organs. The disease process may…
Abstract Number: 134 • 2012 ACR/ARHP Annual Meeting
Co-Existence of Gout in Rheumatoid Arthritis: It Does Happen! A Population Based Study
Adlene Jebakumar¹, Cynthia S. Crowson², P. Deepak Udayakumar¹ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Even though there are a few cases in the literature reporting co-existence of gout and rheumatoid arthritis (RA), it has been a long time…
Abstract Number: 135 • 2012 ACR/ARHP Annual Meeting
A Pilot Study of the Efficacy of IL1 Blockade by Anakinra in Acute Calcific Periarthritis of the Rotator Cuff
Pascal Zufferey¹, Melanie Faucherre², Pierre A. Varisco¹, Berengere Aubry Sr.¹, Isabelle Fabreguet³ and Alexander K. So Sr.¹, ¹Dal/Rhu, CHUV, Lausanne, Switzerland, ²Dal /Rhu, CHUV, Lausanne, Switzerland, ³CHUV, Lausanne, Switzerland
Background/Purpose: Calcific periarthritis of rotator cuff can induce acute and severe shoulder pain and is accompnied by signs of acute inflammation. The calcific deposits are…
Abstract Number: 136 • 2012 ACR/ARHP Annual Meeting
A Delphi Exercise to Identify Characteristic Features of Gout – A Study of Opinions From Patients and Physicians to Inform New Classification Criteria
Rebecca Prowse¹, Nicola Dalbeth², H. R. Schumacher³, Tuhina Neogi⁴, Tim L. Jansen⁵, Jaap Fransen⁶ and William Taylor¹, ¹University of Otago, Wellington, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Boston University School of Medicine, Boston, MA, ⁵Rheumatology, St Radboud University Nijmegen Medical Centre, Netherlands, ⁶Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
A Delphi Exercise to Identify Characteristic Features of Gout - a Study of Opinions from Patients and Physicians to Inform New Classification CriteriaBackground/Purpose: Updated classification…
Abstract Number: 137 • 2012 ACR/ARHP Annual Meeting
Monosodium Urate Crystals Inhibit Tenocyte Viability and Function: Implications for Periarticular Involvement in Chronic Gout
Ashika Chhana¹, Karen E. Callon¹, Bregina Pool¹, Dorit Naot¹, Gregory Gamble², Brendan Coleman³, Fiona M. McQueen⁴, Jillian Cornish¹ and Nicola Dalbeth¹, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Orthopedic Surgery, Middlemore Hospital, Auckland, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Background/Purpose: Recent advanced imaging studies have demonstrated that urate deposition in periarticular structures is common in gout. Urate deposition has been observed both adjacent to…
Abstract Number: 138 • 2012 ACR/ARHP Annual Meeting
Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout
Michael George¹, Sally W. Pullman-Mooar² and H. Ralph Schumacher³, ¹Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, ³Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Colchicine is recommended to prevent gout flares in patients initiating and increasing uric acid lowering therapy until serum uric acid is ≤ 6 mg/dL.…
Abstract Number: 139 • 2012 ACR/ARHP Annual Meeting
Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout
Lisa K. Stamp¹, Christopher Frampton¹, John L. O'Donnell², Jill Drake³ and Peter T. Chapman⁴, ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ³Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁴Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: The key to effective long-term management of gout is sustained reduction of serum urate (SU) Methods: Patients with gout and a SU >0.36mmol/L…
Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting
Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy
Dinesh Khanna¹, Puja Khanna², David Hagerty³, Chris Storgard⁴, Robert Mischler⁵ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical, Ardea Bioscience, San Diego, CA, ⁴4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. The purpose of this study is to describe physician, patient and treatment…
Abstract Number: 141 • 2012 ACR/ARHP Annual Meeting
Effectiveness of Prophylaxis with Anti-Gout Medications On Risk of Gout Attacks
Tuhina Neogi¹, Clara Chen², Jingbo Niu³, Christine E. Chaisson⁴, David J. Hunter⁵, Hyon Choi⁶ and Yuqing Zhang⁷, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Arthritis Center, Boston University School of Public Health, Boston, MA, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁷Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: While a few studies have examined colchicine's ability to prevent gout attacks, NSAIDs have not been formally studied in this regard, despite use of…
Abstract Number: 142 • 2012 ACR/ARHP Annual Meeting
Efficacy of Canakinumab Versus Triamcinolone Acetonide According to Multiple Gouty Arthritis-Related Health Outcomes Measures
Ari Gnanasakthy¹, Andrew Sarkin², Rachel Lale², Kyle Choi² and Jan D. Hirsch³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Health Services Research Center, University of California, San Diego, CA, ³Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, CA
Background/Purpose: Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be a potential therapeutic option for treating acute gout attacks and delaying new attacks…
Abstract Number: 143 • 2012 ACR/ARHP Annual Meeting
Proposed Gout Treatment Guidelines and Meeting Serum Urate and Flare Goals
Jasvinder A. Singh¹, David Hagerty², Chris Storgard³, Robert Mischler⁴ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Medical, Ardea Bioscience, San Diego, CA, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Although gout is a relatively common condition, treatment is often not ideal with many patients continuing to experience multiple flares and some developing complications…
Abstract Number: 144 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Canakinumab in Patients with Gouty Arthritis
Alexander So¹, Reike Alten², H. Ralph Schumacher³, Mark Bloch⁴, Thomas Bardin⁵, Markus R. John⁶, Gerhard Krammer⁶, Jan Michael Nebesky⁶, Aiyang Tao⁷ and Naomi Schlesinger⁸, ¹Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, ²Charité Univ Medicine, Berlin, Germany, ³Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Rheumatology, Hôpital Lariboisière, Paris, France, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits. CAN…
Abstract Number: 145 • 2012 ACR/ARHP Annual Meeting
Prevalence of Non-Gout Arthritis in Patients with Gout: Not As Sparing As Previously Thought
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: the presence of other chronic inflammatory disease has been historically and academically thought to be “protective” conditions for the development of gout. Objective: to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].